Revance downgraded to Hold from Buy at Stifel

Stifel downgraded Revance to Hold from Buy with a price target of $6.66, down from $20, after the company entered into a merger agreement pursuant to which Crown Laboratories will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924M.